The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000719336p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
25/03/2026
Date registered
Help: Date registered
16/06/2026
Date last updated
Help: Date last updated
16/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Olanzapine for weight loss prevention in patients with head and neck cancer undergoing curative intent chemotherapy with radiotherapy
Scientific title
OLIVE: Olanzapine to prevent critical weight loss in head and neck cancer patients undergoing combined chemoradiotherapy with curative intent: A phase 2 trial
Additional trial identifiers [1] 316872 0
Nil known
Universal Trial Number (UTN)
U1111-1337-9884
Trial acronym
OLIVE
Related trial records

Health condition
Health condition(s) studied:
Head and Neck Cancer 341268 0
Weight Loss 341269 0
Condition category
Condition code
Cancer 337345 337345 0 0
Head and neck
Diet and Nutrition 338104 338104 0 0
Other diet and nutrition disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Olanzapine 2.5mg oral, daily, continually for 12 weeks. Commencing within 2 weeks prior to combined chemoradiotherapy and completing 12 weeks of olanzapine thereafter.
Adherence will be assessed with a drug diary and participants will return all unused olanzapine and empty packaging to the delegated site staff.
Intervention code [1] 333572 0
Treatment: Drugs
Description of the comparator or control
The control group is historic, where they only receive standard of care combined chemoradiotherapy. Data is from the medical record. These data are collected from a local audit that was conducted at Fiona Stanley Hospital from 01/01/2023 to 31/03/2023.
Shenton S HL, Holgate B,. Audit of Weight Loss During Radiotherapy. Fiona Stanley Hospital, Governance, Evidence, Knowledge, Outcomes - GEKO. 2023.
Control group
Historical

Outcomes
Primary outcome [1] 344866 0
Incidence of critical weight loss (>5% of body mass)
Timepoint [1] 344866 0
At least every 2 weeks for the duration of trial. (up until 12 weeks post combined chemoradiotherapy)
Secondary outcome [1] 459556 0
Mean / median weight change
Timepoint [1] 459556 0
at least 2 weekly for duration of trial (until 12 weeks post combined chemorads)
Secondary outcome [2] 459557 0
Nasogastric tube insertion rate
Timepoint [2] 459557 0
Assessed at weigh ins. i.e. At least every 2 weeks for the duration of trial. (up until 12 weeks post combined chemoradiotherapy). If positive, medical record will be reviewed for specific insertion date.
Secondary outcome [3] 459560 0
Adverse events
Timepoint [3] 459560 0
Assessed at weigh ins. i.e. At least every 2 weeks for the duration of trial. (up until 12 weeks post combined chemoradiotherapy).

Eligibility
Key inclusion criteria
1. Age greater than or equal to 18 years at the time of enrolment.
2. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
3. Head and neck cancer (oropharynx, hypopharynx, larynx) planned for definitive combined chemoradiotherapy.
4. Patients taking oral diet.
5. Adequate organ function. ANC > 1.0 x 109/L, platelet > 100 x 109/L, Creatinine clearance >15 ml/min, Bilirubin = 30 mg/L.
6. Ability to consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Patients requiring adjuvant chemoradiotherapy post-surgery.
2. Patients requiring induction chemotherapy before definitive chemoradiotherapy.
3. Patients requiring insertion of invasive feeding device before chemoradiotherapy commences.
4. BMI > 30 kg/m2.
5. Intake of olanzapine for more than 3 days per week for any other indications.
6. Patients already taking any regular antipsychotic.
7. Patients with a significant mental health history that may be affected by participation in the study, clinician discretion.
8. Regular use of systemic corticosteroids (up to 4 days of dexamethasone for each cisplatin dose is permitted).
9. Pregnancy.
10. Baseline QTc greater than 480 ms.
11. Poorly controlled diabetes, HbA1c > 9.5%.
12. Allergy or intolerance to olanzapine.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Historical control is the cohort that was analysed during an audit between 01/01/2023 and 31/03/2023. Patients commencing definitive chemorads at Fiona Stanley Hospital for head and neck cancer during this time and completed their treatment.
Shenton S HL, Holgate B,. Audit of Weight Loss During Radiotherapy. Fiona Stanley Hospital, Governance, Evidence, Knowledge, Outcomes - GEKO. 2023
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The primary endpoint will be analysed by a single-arm binomial chi-squared test. There will be no interim analysis.
Categorical data will be analysed by percentages. Continuous data will be analysed by descriptive statistics such as average, median, standard deviation and tertiles/quartiles where appropriate

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29308 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 45626 0
6150 - Murdoch

Funding & Sponsors
Funding source category [1] 321470 0
Hospital
Name [1] 321470 0
Fiona Stanley Hospital
Country [1] 321470 0
Australia
Primary sponsor type
Hospital
Name
Fiona Stanley Hospital
Address
Country
Australia
Secondary sponsor category [1] 324219 0
None
Name [1] 324219 0
Address [1] 324219 0
Country [1] 324219 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320003 0
WA Health Central HREC
Ethics committee address [1] 320003 0
Ethics committee country [1] 320003 0
Australia
Date submitted for ethics approval [1] 320003 0
18/03/2026
Approval date [1] 320003 0
Ethics approval number [1] 320003 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149110 0
Dr Wade Huish
Address 149110 0
Fiona Stanley Hospital, 11 Robyn Warren Dve, Murdoch WA. 6150
Country 149110 0
Australia
Phone 149110 0
+61861526530
Fax 149110 0
Email 149110 0
Contact person for public queries
Name 149111 0
Gabriella Marsavela
Address 149111 0
Fiona Stanley Hospital, 11 Robyn Warren Dve, Murdoch WA. 6150
Country 149111 0
Australia
Phone 149111 0
+61861526530
Fax 149111 0
Email 149111 0
Contact person for scientific queries
Name 149112 0
Gabriella Marsavela
Address 149112 0
Fiona Stanley Hospital, 11 Robyn Warren Dve, Murdoch WA. 6150
Country 149112 0
Australia
Phone 149112 0
+61861526530
Fax 149112 0
Email 149112 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Nil sharing of data required in study



What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Informed consent form    OLIVE FSH Main PICF_V1.0_16Mar2026_clean.docx
Study protocol    OLIVE Protocol V1.0_16Mar2026_clean.docx


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.